Merkel Cell
Carcinoma (MCC) Treatment Market: Introduction
·
Merkel cell carcinoma, also known as neuroendocrine carcinoma of the
skin, is a rare and aggressive type of skin cancer that develops from the top
layers of the skin. The disease is caused due to prolonged exposure to the sun,
weak immunity, or due to idiopathic reasons.
Request Brochure –
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=56184
·
Merkel cell carcinoma (MCC) is a rare disease in which malignant cancer
cells form in the skin. Merkel cell carcinoma is the second-most common cause
of skin cancer death after melanoma. Weak immune system and exposure to the sun
induce the effects of merkel cell carcinoma. MCC usually appears as a single
painless lump when exposed to the sun. The disease starts in areas of skin
exposed to the sun, especially the head and neck, as well as the arms, legs, and
trunk. Merkel cell carcinoma grows rapidly into a metastasize at an early
stage, by spreading to nearby lymph nodes or skin in distant parts of the body,
lungs, brain, bones, or other organs.
·
Several tests and procedures can be carried to examine the skin to
detect and diagnose carcinoma cells; however, there are certain factors or
effects of prognosis and treatment options that decrease the chance of
recovery. New developments in skin biopsy approaches enable to image the
diseases or infection at the cellular and molecular level, paving the way for
early diagnosis and treatment of diseases.
Request COVID Analysis on Merkel
Cell Carcinoma (MCC) Treatment Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=56184
Key Drivers,
Restraints, and Opportunities of Global Merkel Cell Carcinoma (MCC) Treatment
Market
·
Increasing cases of MCC is a prominent factor propelling the global
Merkel cell carcinoma market. As per the report published in the Current
Dermatology Reports journal, the estimated annual prevalence of MCC was
approximately 0.6 per 100,000 people. The National Cancer Database, has
reported that each year approximately 2500 and 1500, novel MCC cases are
reported in Europe and the U.S., respectively.
·
Rising research and development activities for the treatment of Merkel
cell carcinoma is anticipated to propel the market. In May 2017, researchers of
Fred Hutchison University and the University of Washington in Seattle reported
the results of a small study combining Avelumab with two other treatments. The
combination therapy improves T cells generation and attacks the MCC cells. The
National Cancer Institute has also commenced a clinical trial involving the
investigational study of the drug ipilimumab Merkel cell carcinoma. Curalso
recently is in phase 2 clinical study.
·
The Merkel cell carcinoma pipeline is anticipated to propel the market.
For instance, in December 2018, Merck Sharp & Dohme Corp., a subsidiary of
Merck & Co., Inc., undertook a phase 3 open-label, single-arm study to
evaluate the efficacy of pembrolizumab as first-line therapy in the
participants with advanced Merkel cell carcinoma. In December 2018, Incyte Corporation
undertook a phase 2 study of INCMGA00012 in participants with metastatic Merkel
cell carcinoma.
·
The presence of biosimilars for the Merkel cell carcinoma therapy
have been observed to fuel the market. For instance, the European Commission
approved the first biosimilars Amgevita, from the Amgen pharmaceutical company.
It was approved in the US by the FDA, in September 2016.
·
However, the high price of therapeutics, lack of awareness among the
people, the onset of side-effects are likely to hamper the market during the
forecast period. Side-effects of external radiation therapy include nausea,
skin changes, diarrhoea, painful sores in the throat and mouth, fatigue, and
dry mouth or thick saliva. The side-effects of the radiation are temporary;
however, some rare serious side-effects could become permanent. In a few cases,
radiation to the chest could even cause lung damage, which may lead to
breathing issues and shortness of breath.
Request Customization on
Merkel Cell
Carcinoma (MCC) Treatment Market Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=56184
North America to
Capture Major Share of Global Merkel Cell Carcinoma (MCC) Treatment Market
In terms of region, the global merkel
cell carcinoma treatment market can be segmented into North America, Latin
America, Europe, Asia Pacific, and Middle East & Africa. North America
dominated the global market due to an increase in funding for the development
of research and healthcare infrastructure in the region. Rising incidence of
skin cancer diseases, such as MCC, and early phase diagnosis and treatment of
diseases are driving the biotechnology & pharmaceutical sector in North America,
which in turn is expected to boost the Merkel cell carcinoma (MCC) treatment
market in the region in the next few years. Europe is the second-leading market
for Merkel cell carcinoma treatment, as there are favorable government policies
regarding the development of healthcare infrastructure, well-developed
facilities for cancer patients, and increasing number of gene therapy companies
in the region. The Merkel cell carcinoma (MCC) treatment market in Asia
Pacific is projected to expand at a rapid pace during the forecast period due
to rising environmental pollution, changing lifestyle of people, increasing
awareness among patients about MCC treatment, and growing per capita
expenditure for health insurance in the region. Moreover, economic growth in India
and China is boosting healthcare infrastructure as well as expansion of
pharmaceutical companies and biotech labs, which is likely to drive the Merkel
cell carcinoma (MCC) treatment market in Asia Pacific in the near future.
Pre Book Merkel Cell Carcinoma (MCC) Treatment Market Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=56184<ype=S
Key Players
Operating in Global Merkel Cell Carcinoma (MCC) Treatment Market
The global merkel cell carcinoma
(MCC) treatment market is highly fragmented, with the presence of various key
players. A large number of manufacturers hold a major share in their
respective regions. Major players operating in the global merkel cell carcinoma
(MCC) treatment market are:
·
Pfizer Inc.
·
Ono Pharmaceutical Co. Ltd
·
Bristol-Myers Squibb Company
·
Merck & Co., Inc.
·
Amgen Inc.
·
AstraZeneca
·
Novartis AG
·
Oncovir, Inc.
·
Teva Pharmaceuticals Industries Ltd
·
OncoSec Medical Incorporated
·
Biologics, Inc. (McKesson Corporation)
·
Millennium Pharmaceuticals, Inc.
·
NantKwest, Inc.
·
Merck KGaA
·
BeiGene Ltd.
·
Apcure SAS
·
Immune Design Corp.
·
Others
About Us
Transparency Market Research is a global market intelligence company,
providing global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers. Our experienced team of analysts,
researchers, and consultants use proprietary data sources and various tools and
techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and information.
With a broad research and analysis capability, Transparency Market Research
employs rigorous primary and secondary research techniques in developing
distinctive data sets and research material for business reports.
Contact
Transparency Market Research
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com
